Dr. Drilon on Results of the Phase I/II LIBRETTO-001 Trial
Alexander Drilon, MD, research director, Memorial Sloan Kettering Cancer Center, discusses the results of LIBRETTO-001, a phase I/II trial of RET inhibitor, selpercatinib in patients with RET fusion non-small cell lung cancers.
Alexander Drilon, MD, research director, Memorial Sloan Kettering Cancer Center, discusses the results of LIBRETTO-001, a phase I/II trial of RET inhibitor, selpercatinib in patients with RET fusion non-small cell lung cancers (NSCLC).
To date, the LIBRETTO-001 trial has treated 105 patients across NSCLCs and shows a 68% response rate, with some cases of complete response to selpercatinib.
Drilon says, this trial serves an unmet need in NSCLC, since there is no approved targeted therapy for RET fusion NSCLC.
Related Videos
Related Content
